These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Femigen forte and mite preparations in contraception and gynecologival disorders].
    Author: Sternadel Z, Pietrusiewicz W, Wasilewska B.
    Journal: Ginekol Pol; 1970 Nov; 41(11):1227-36. PubMed ID: 4098877.
    Abstract:
    Femigen forte (chlormadinone 3 mg + mestranol .1 mg) was administered to 90 women and Femigen mite (chlormadinone 2 mg + .084 mg of mestranol) was administered to 43 women, both groups aged 19-47 years, as a contraceptive and as therapy for endometriosis, dysmenorrhea, irregular and profuse menstruations, in the incipient phase of climax, and in diagnostics. Both drugs were observed to be 100% effective as contraceptives. Side effects such as nausea, intermenstrual bleedings, and absence of menstruation were most often observed with Femigen forte; about 30% of these users. Most side effects occurred in the first 2 cycles. Those using Femigen mite showed almost no side effects. No increase in the concentration of blood glucose was noted with either preparation. The effect of these drugs on the vaginal lining and on the endometrium was weak. No thromboembolic complications were observed. The low-dose preparation was recommended more for contraception. An estrogenic content of about .05 mg creates the same effect and decreases the occurrence of side effects.
    [Abstract] [Full Text] [Related] [New Search]